StemMACS™ HSC-CFU Media, human

StemMACS™ HSC-CFU Media, human

StemMACS HSC-CFU Media have been developed for the expansion of CD34
cells and to assess the differentiation potential of human hematopoietic stem and progenitor cells as Colony Forming Units (CFU). They are ideally suited for use with
  • unseparated blood3 , bone marrow4 , or fetal liver cells
  • sorted cell populations1,4
  • or ES and iPS cell-derived hematopoietic precursors2
StemMACS HSC-CFU Media are standardized semi-solid media based on methylcellulose in IMDM, supplemented with FBS, BSA, and different growth factors. StemMACS HSC-CFU media are designed to maximize growth and differentiation of progenitor cells and allow the clonal progeny of a single cell to grow in a distinct cluster or colony. They are produced under tightly controlled manufacturing conditions and use highly qualified raw materials to provide a consistent and optimally performing colony assay.
StemMACS HSC-CFU media are available in different formats.

Technical data

Formulation of StemMACS HSC-CFU media

Technical data

Formulation of StemMACS HSC-CFU media
  • Selected references

    1. Lambert et al. (2009)
      In essential thrombocythemia, multiple
      -V617F clones are present in most mutant-positive patients: a new disease paradigm.
      Blood 114: 3018-3023
    2. Tormin et al. (2011)
      CD146 expression on primary nonhematopoietic bone marrow stem cells is correlated with
      in situ
      Blood 117: 5067-5077
    3. Zhou et al. (2011) The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML. Blood 118: 2830-2839
    4. Bissels et al. (2011)
      Combined characterization of microRNA and mRNA profiles delineates early differentiation pathways of CD133
      and CD34
      hematopoietic stem and progenitor cells.
      Stem Cells 29: 847-857
    5. Liu, G.H. et al. (2014) Modelling Fanconi anemia pathogenesis and therapeutics using integration-free patient-derived iPSCs. Nat Commun 5: 4330
    6. Brault, J. et al. (2014)
      Optimized generation of functional neutrophils and macrophages from patient-specific induced pluripotent stem cells:
      ex vivo
      models of X
      -linked, AR22
      - and AR47
      - chronic granulomatous diseases.
      Biores Open Access 3(6): 311-326
    7. Venton, G. et al. (2016) Aldehyde dehydrogenases inhibition eradicates leukemia stem cells while sparing normal progenitors. Blood Cancer J. 6(9): 469
    8. Del Fante, C. et al. (2005)
      Immunomagnetic cell selection performed for HLA haploidentical transplants with the CliniMACS device: effect of additional platelet removal on CD34
      cell recovery.
      Stem Cells Dev. 14: 734-739
    9. Chang et al. (2006) Definitive-like erythroid cells derived from human embryonic stem cells coexpress high levels of embryonic and fetal globins with little or no adult globin Blood 108: 1515-1523
    10. Biedermann, B. et al. (2007) Analysis of the CD33-related siglec family reveals that Siglec-9 is an endocytic receptor expressed on subsets of acute myeloid leukemia cells and absent from normal hematopoietic progenitors. Leuk. Res. 31: 211-220
    11. Watts et al. (2008) Cytotherapy 10(suppl. 1): poster no. 150
  • Brochures and posters

  • Scientific posters

Product options: 4

StemMACS HSC-CFU complete with Epo, human

100 mL
CHF  642.00

StemMACS HSC-CFU complete w/o Epo, human

100 mL
CHF  588.00

StemMACS HSC-CFU lite with Epo, human

100 mL
CHF  574.00

StemMACS HSC-CFU basic, human

80 mL
CHF  214.00

Related products

4 products available